The Smad family proteins are critical components of the transforming growth factor (TGF)-b signaling pathway. TGF-b is a multipotent cytokine that elicits many biological functions. In particular, TGF-b exhibits eects on the cell cycle manifested by G1-phase arrest, dierentiation, or apoptosis of several target cells, suggesting that disruption of TGF-b signaling pathway could be involved in cancer formation. Here we show one missense mutation of the Smad4 gene in the MH1 domain (P102L) and one frame shift mutation resulting in termination in the MH2 domain (D(483 ± 552)) in acute myelogeneous leukemia. Both of the mutated Smad4 proteins lack transcriptional activities. Concomitant expression of the P102L mutant with wild-type Smad4 inactivates wild-type Smad4 through inhibiting its DNA-binding ability. The D(483 ± 552) mutant blocks nuclear translocation of wild-type Smad4 and thus disrupts TGF-b signaling. This is the ®rst report showing that mutations in the Smad4 gene are associated with the pathogenesis of acute myelogeneous leukemia and the obtained results should provide useful insights into the mechanism whereby disruption of TGF-b signaling pathway could lead to acute myelogeneous leukemia. Oncogene (2001) 20, 88 ± 96.
Introduction
Smads are a class of proteins that function as intracellular signaling eectors for TGF-b superfamily, which includes TGF-b, activins, and bone morphogenetic proteins (BMPs) Massague, 1998) . TGF-b regulates a broad range of cellular process from proliferation to dierentiation and apoptosis (Zhang and Derynck, 1999) . It plays an important role in tumor development, and TGF-b signaling pathway can be considered as a tumorsuppressor pathway for carcinomas. Smads can be divided into three distinct subclasses; receptor-activated Smads (R-Smads), common-partner Smads (CoSmads), and inhibitory Smads (anti-Smads). Smad2 and Smad3 are R-Smads that transmit TGF-b/activin signals, whereas Smad1, Smad5, and Smad8 act as RSmads mediating BMP signals. Smad4 is the only CoSmad identi®ed in mammals. R-Smads and Co-Smads are homologous in their amino and carboxyl termini, which are called as the MH1 and MH2 domains, respectively. These domains are connected by a prolinerich linker region. Upon ligand stimulation, R-Smads are phosphorylated by the serine/threonine kinase receptors, form complexes with Co-Smad, and translocate into the nucleus, where they cooperatively regulate transcription of target genes. Smad4 plays a critical role in signaling by TGF-b, illustrated by the absence of TGF-b signaling and R-Smad functioning in Smad4-de®cient tumor-cell lines, as well as by the synergistic action of Smad4 with R-Smads in transcriptional activation of target genes and induction of mesoderm (Nakao et al., 1997; Lagna et al., 1996; de Winter et al., 1997; Liu et al., 1997; Zhang et al., 1997) . The importance of the Smad4 function is also shown by its activity as a tumor suppressor; mutation or deletion of the Smad4 gene is often associated with tumorigenesis Schutte et al., 1996; Shi et al., 1997; Le Dai et al., 1998; Zhou et al., 1998) . Cell lines expressing the Smad4 mutants found in human cancers failed to transcriptionally activate transfected luciferase reporters containing the Smad-binding element .
In our recent study, we showed that the oncoprotein Evi-1 that may be involved in leukemic transformation of hematopoietic cells represses TGF-b signaling by inhibiting Smad3 (Kurokawa et al., 1998b) . This indicates that disruption of the TGF-b signaling pathway could be involved in formation of human hematological malignancies. Here, we have identi®ed two mutations of the Smad4 gene in acute myelogeneous leukemia (AML). One case with AML exhibited a missense mutation that causes a single amino acid change in the MH1 domain. We have also found a frame shift mutation resulting in truncation in the carboxyl terminus of the MH2 domain in the CTV-1 cell line, a human cell line derived from acute monocytic leukemia (Drexler et al., 1986) . Both of the resultant mutants have lost the ability to activate transcription. Furthermore, we have found both mutants act as dominant negative inhibitors of wildtype Smad4 through blocking the DNA-binding or the nuclear translocation ability of wild-type Smad4. They can interrupt growth-inhibitory signals triggered by TGF-b when expressed in 32Dcl3 cells, a murine IL-3-dependent immature myeloid cell line. These results suggest that mutations in the Smad4 gene are associated with pathogenesis of acute myelogeneous leukemia and provide useful insights into the mechanism whereby the disruption of TGF-b signaling pathway could lead to acute myelogeneous leukemia.
Results

Mutations of the Smad4 gene in acute myelogeneous leukemia
The previous studies on Smad proteins revealed that the MH1 domain has a DNA-binding ability Zhang et al., 1998; Jonk et al., 1998; Hua et al., 1998; Feng et al., 1998; Dennler et al., 1998) and the MH2 domain is responsible for homo-and heteromerization between the Smad proteins (Lagna et al., 1996; Wu et al., 1997; Nakao et al., 1997; Kawabata et al., 1998; Shi et al., 1997) . The mutations of the Smad4 gene found in pancreatic and colon cancers are mainly located in the MH1 or MH2 domain Le Dai et al., 1998; Shi et al., 1997) . These facts allowed us to investigate mutational changes within the eight exons (exons 1 ± 3 and 7 ± 11) of the Smad4 gene which include the MH1 and MH2 domains in human myelogeneous leukemia. We screened 12 cell lines established from the patients with acute myelogeneous leukemia (AML) and 22 cases with AML using the reverse transcriptasepolymerase chain reaction-single-strand conformation polymorphism (RT ± PCR ± SSCP) method. The speci®c subtypes according to French ± American ± British (FAB) criteria (Bennett et al., 1991) of the cases analysed are as follows; three cases of M1, nine cases of M2, three cases of M3, two cases of M4 and ®ve cases of M5. Abnormally migrating bands were detected from the samples of a case with AML (M1) and of the CTV-1 cell line, which was established from a case with acute monocytic leukemia (Drexler et al., 1986) (Figure 1 ). The sequencing analyses showed nucleotide alterations of the Smad4 gene in exon 2 for the patient with AML, and in exon 11 for CTV-1 cells. The sample from the case with AML revealed a missense mutation at codon 102 (P102L; CCT to CTT), which is located in the MH1 domain of Smad4 (Figure 2 ). The mutation found in CTV-1 cells was AATA insertion at codon 483 resulting in carboxyterminal truncation (D(483 ± 552)) (Figure 2 ). The sequencing analysis of the genomic DNA of CTV-1 cells revealed a splice donor site mutation after exon 10, which was found in a pancreatic carcinoma in the previous study . In either case, both the normal and the mutated sequences were obtained, conforming to the results from the RT ± PCR ± SSCP analysis, in which both normally and abnormally migrating bands were detected (Figure 1 ). Almost all of the mononuclear cells of the sample derived from the case with AML were leukemic cells. These results suggest that in each case, the mutation is heterozygous and the normal sequence is present in the corresponding sites of the other allele. However, we could not determine whether the Smad4 gene is mutated at the germ line or the somatic level because samples of the normal tissue are not available in both cases.
The Smad4 mutants found in AML inhibit Smad4-induced transcriptional activation of the PAI-1 promoter
To determine functional consequences of the mutations in the Smad4 gene, we ®rst tested whether these mutations could inactivate Smad4-induced transcriptional activation. When the expression vectors for wildtype Smad3 and Smad4 were cotransfected into HepG2 cells with p3TP-Lux, a TGF-b-responsive reporter plasmid consisting of the plasminogen-activator inhibitor-1 (PAI-1) promoter (Wrana et al., 1994) , a signi®cant increase in luciferase activity was observed (Figure 3a ,b, lane 2). When the expression vectors for Smad3 and Smad4P102L were cotransfected, we observed a marked reduction of the PAI-1 promoter (Figure 3a , lane 4). These results indicate that Smad4P102L acts as a dominant negative inhibitor of wild-type Smad4. The Smad4D(483 ± 552) mutant has also lost the transcriptional activity (Figure 3b, lane 3) . This mutant again repressed the transcriptional activity of wild-type Smad4 in a dominant negative manner (Figure 3b, lane 4) .
The Smad4 mutants physically interact with the wild-type Smad3 and Smad4
In the previous study, it was shown that the MH2 domains of Smad3 and Smad4 could form homo-and heteromeric trimers. Smad4 plays a central role as it is a shared hetero-oligomerization partner of the other Smads (Shi et al., 1997) . These results indicate that this complex formation plays an important role in the function of Smad4. To de®ne the mechanism of transcriptional inhibition by the Smad4 mutants, we evaluated the interactions of the Smad4 mutants with wild-type Smad3 or Smad4. Wild-type Smad4 was coprecipitated by GST-Smad3 bound to glutathione beads when both proteins were overexpressed in COS-7 cells even in the absence of TGF-b stimulation, showing formation of the Smad3-4 complex ( Figure  4a , lane 2). These results are consistent with the previous report that Smad3-4 complex formation is observed without TGF-b stimulation when they are expressed in COS-7 cells (Wu et al., 1997) . In these experiments, both of the two mutants of Smad4, P102L and D(483 ± 552), were also coprecipitated by GSTSmad3 ( Figure 4a , lanes 4 and 6). These results indicate that both of the Smad4 mutants found in leukemia were able to form a heteromeric complex with wild-type Smad3. Furthermore, we investigated whether the Smad4 mutants could physically interact with wild-type Smad4 using the coprecipitation assays. Smad4-HA was coimmunoprecipitated with wild-type Smad4-Flag ( Figure 4b , lane 2). In the same experiment, Smad4-HA was coimmunoprecipitated with the Flag-tagged form of Smad4P102L or Smad4D(483 ± 552) ( Figure 4b , lanes 3 and 4). These results indicate that both mutants retain the abilities to form heteromeric complexes with wild-type Smad3 and Smad4.
Subcellular localization of the Smad4 mutants
Our transcriptional response assays and in vivo binding assays showed that the carboxy-terminally truncated mutant retains the abilities to form a complex with Smad3 or Smad4, while it inactivates the Smad4-induced transcriptional activation. To de®ne the mechanism for the inhibitory eect of Smad4D(483 ± 552), we examined subcellular localizations of wild-type Smad4 and Smad4D(483 ± 552) when they were coexpressed in COS-7 cells using immuno¯uorescent staining. Wild-type Smad4-HA was coexpressed with Smad4-Flag in COS-7 cells and the cells were stained with the anti-HA and the anti-Flag antibodies. Both of them colocalized predominantly in the cytoplasm of the cells in the absence of the ligand ( Figure 5A , a, c, and e). Upon stimulation with TGF-b, they signi®cantly accumulated in the nucleus ( Figure 5A , b, d, and f). These results indicate that wild-type Smad4 exists in a homomeric complex in the cytoplasm, which is translocated into the nucleus upon ligand stimulation. In contrast, when Smad4-HA was coexpressed with the Flag-tagged form of Smad4D(483 ± 552) in COS-7 cells, we observed cytoplasmic colocalization of them in the absence of ligand ( Figure 5B , a, c, and e), which remained unaltered upon TGF-b stimulation ( Figure  5B , b, d, and f). These data suggest that Smad4D(483 ± 552) has lost the ability to translocate into the nucleus and con®nes wild-type Smad4 into the inactive complex that persists in the cytoplasm regardless of ligand stimulation. Thus, Smad4D(483 ± 552) would act as a dominant negative inhibitor of wild-type Smad4 through blocking nuclear translocation of wild-type Smad4.
We next coexpressed Smad4-HA with the Flagtagged form of Smad4P102L in COS-7 cells and stained the cells with the anti-HA and the anti-Flag antibodies to evaluate the ability of Smad4P102L to translocate into the nucleus upon TGF-b stimulation. We observed that cytoplasmic colocalization in the absence of ligand, which was replaced by nuclear accumulation upon TGF-b stimulation ( Figure 5C ). These ®ndings indicate that Smad4P102L retains the ability to translocate into the nucleus upon TGF-b stimulation and does not aect nuclear translocation of wild-type Smad4.
Analyses of the DNA-binding ability of Smad4P102L
Using a PCR-based selection procedure, an 8 bp palindromic DNA sequence (GTCTAGAC) was selected from a random pool of oligonucleotides as the optimal Smad-binding element (SBE) for both Smad3 and Smad4 . Recently, it was shown that Smad4 binds to the region between 7688 and 7660 upstream of the initiation site in the PAI-1 promoter containing SBE with a single A to G change at position 5 (SBE, GTCTAGAC; PAI-1 7684/7677, GTCTGGAC) (Stroschein et al., 1999) . Using a double-stranded oligonucleotide containing this region as a probe (Stroschein et al., 1999) , we investigated the DNA-binding ability of Smad4P102L by the electrophoretic mobility shift assay (EMSA). We expressed Smad4-Flag in 293 cells and isolated Smad4-Flag by immunoprecipitation from the cell lysates of 293 cells using the anti-Flag antibody. The probe was incubated with the isolated Smad4-Flag and then the complexes were electrophoresed. We observed a signi®cantly shifted band ( This band was not detected when we used a mutant probe in which SBE was changed to a sequence dierent from the consensus sequence (Stroschein et al., 1999) (data not shown). On the other hand, no band was detected when the probe was incubated and electrophoresed with the Flag-tagged form of P102L ( Figure 6 , lane 4), indicating that P102L has lost the DNA-binding ability. This accounts for loss of the transcriptional activity of P102L (Figure 3a) . Furthermore, we evaluated whether P102L aects binding of wild-type Smad4 to SBE. Remarkably, there was a marked reduction of the amount of the DNASmad4WT complex in the presence of P102L ( Figure  6 , lane 5). These results suggest that concomitant expression of P102L with wild-type Smad4 inhibits the DNA-binding ability of wild-type Smad4 to SBE. Because Smad4-induced transcription from the PAI-1 promoter is dependent on binding to SBE (Stroschein et al., 1999) , these ®ndings account for the mechanism whereby the P102L mutant acts as a dominant negative inhibitor of wild-type Smad4 in the transcriptional response assays (Figure 3a) .
Constitutive expression of the Smad4 mutants in 32Dcl3 cells overcomes TGF-b-mediated inhibition of cellular growth
Given the data from the experiments indicating that the Smad4 mutants can perturb TGF-b signaling, we examined whether the Smad4 mutants aect the antiproliferative eects of TGF-b on hematopoietic cells. To this end, we used 32Dcl3 cells, a murine IL-3-dependent immature myeloid cell line, which undergo growth arrests in response to TGF-b (Ohta et al., 1987; Kurokawa et al., 1998a) . We introduced expression vectors for Smad4P102L or Smad4D(483 ± 552) (pMEneo-P102L or pMEneo-D(483 ± 552)) that enable concomitant expression of the neomycin resistant gene in 32Dcl3 cells and selected them for neomycin resistance in the presence of G418 (Life Technologies, Inc., Gaithersburg, MD, USA). Individual G418-resistant clones were screened for expression of the Flag-tagged form of P102L or D(483 ± 552), and several stable 32Dcl3 cell lines that express the Smad4 mutants were isolated. Western blot analyses using the anti-Flag antibody showed that P1, P5, and P2 are individual clones with dierent expression levels of Smad4P102L (Figure 7a, lanes 3, 4, and 5 ) and D11 and D22 are representative clones expressing Smad4D(483 ± 552) (Figure 7b, lanes 3 and 4) . The level of expression of Smad4P102L in P5 was less than that in P1. P2 expressed the least amount of Smad4P102L among the three clones. Two independent clones, N1 and N3, which were transfected with the empty pMEneo vector were used as controls (Figure 7a ,b, lanes 1 and 2). When cultured in complete medium without TGF-b, all these clones showed comparable viabilities and proliferative abilities with each other (data not shown). We examined the eects of TGF-b on growth of these stable transfectants of 32Dcl3 cells. When cultured with a combination of IL-3 and TGF-b, the proliferation of N1 and N3 was suppressed (Figure 7c,d) . In contrast, P1 and P5, which express Smad4P102L, proliferated even in the presence of TGF-b in an expression-level dependent manner (Figure 7c ). The proliferation of P2, which expressed the least amount of Smad4P102L, was suppressed almost to the control level by TGF-b (Figure 7c) . Furthermore, proliferation of D11 and D22 was not suppressed in the presence of IL-3 and TGF-b (Figure 7d ). These results indicate that the stable clones expressing P102L or D(483 ± 552) show diminished responsiveness to the TGF-b-induced growth-inhibitory signaling. To support these results, we examined whether CTV-1 cells, which harbor Smad4D(483 ± 552), are resistant to TGF-b-mediated growth inhibition or not. Jurkat cells, which are known to be resistant to TGF-b, proliferated even in the presence of various concentrations of TGF-b (Figure  8b ), while proliferation of KG-1 cells in which TGF-b signaling is intact (Piacibello et al., 1991) was suppressed in the presence of TGF-b in a dose dependent manner (Figure 8a ). CTV-1 cells also proliferated with various concentrations of TGF-b (Figure 8c ) and were resistant to TGF-b-mediated growth inhibition. Thus, both Smad4P102L and SmadD(483 ± 552) can interrupt growth-inhibitory signals triggered by TGF-b in hematopoietic cells.
Discussion
In this study, we analysed mutations of the Smad4 gene in human myelogeneous leukemia by the RT ± PCR ± SSCP method. The Smad4 gene was ®rst identi®ed as a tumor suppressor gene, being either mutated or deleted in a signi®cant percentage of pancreatic cancer as well as in a smaller percentage of colon cancer and breast cancer . In the previous studies, no loss or mutation was detected in hematological malignancies (Kaneko et al., 1998) . However, we found the two (5.9%) mutations of the Smad4 gene in human myelogeneous leukemia. Recently, we showed that Evi-1 and its chimeric product, AML1/Evi-1, both of which is thought to play a role in leukemogenesis, physically interact with Smad3, thereby blocking TGF-b-mediated signaling and its growth inhibitory eects (Kurokawa et al., 1998a and b) . These results suggest that disruption of TGF-b-mediated signaling by the mutations of the Smad genes could play an important role in leukemogenesis.
In the present study, RT ± PCR ± SSCP and sequencing analyses showed that both mutations were Figure 8 CTV-1 cells are resistant to TGF-b-mediated growth inhibition. KG-1 (a), Jurkat (b), or CTV-1 (c) cell lines were cultured with 0, 1, or 2.5 ng of TGF-b per ml and 10% FCS. The means and the standard deviations of two independent wells are shown. Two independent experiments were performed and similar results were obtained heterozygous and that a normal allele was still present in each case. In our transcriptional response assays, both mutants failed to activate transcription. Furthermore, they inhibit Smad4-induced transcriptional activation in a dominant negative manner. These results indicate that these mutations, although they are heterozygous, could abolish the function of Smad4 and that loss of the Smad4 function could be related to pathogenesis of human leukemia.
The P102L mutation found in a case with AML is located in the MH1 domain. The MH1 domain of Smad4 has a DNA-binding ability. In this report, we show that Smad4P102L retains the ability to form oligomeric complexes and to translocate into nucleus upon ligand stimulation. However, it lacks both the binding ability to SBE and the transcriptional activity on the PAI-1 promoter. Furthermore, concomitant expression of Smad4P102L with wild-type Smad4 inhibits Smad4-induced transcriptional activation through blocking DNA binding of wild-type Smad4 to SBE. Our study is the ®rst report that elucidates the mechanism whereby the mutant Smad4 with a missense mutation in the MH1 domain acts as a dominant negative inhibitor of wild-type Smad4.
The D(483 ± 552) mutation found in CTV-1 cells is located in the MH2 domain. Determination of the crystal structure of the MH2 domain of Smad4 shows that it associates as a homotrimer (Shi et al., 1997) . Available data now suggest that hetero-oligomeric Smads consisting of Smad3 and Smad4 also form trimers upon ligand stimulation followed by translocation into nucleus . Here, we showed that Smad4D(483 ± 552) lacks the ability to translocate into the nucleus upon ligand stimulation. On the other hand, Smad4D(483 ± 552) retains the ability to oligomerize. These results indicate that complex formation involving Smad4D(483 ± 552) prevents wild-type Smad3 and Smad4 from translocating into the nucleus upon TGF-b stimulation. The similar mechanism of inhibition is reported in the D(515 ± 552) mutation found in pancreatic cancer Hahn et al., 1996) . Taken together, the region between amino acids 515 and 552 of Smad4 should be responsible for nuclear translocation of Smad4, while the region between amino acids 483 and 552 is dispensable for hetero-and homomerization of Smad4.
In this study, we showed that the mutations of the Smad4 gene found in leukemia block the antiproliferative eect of TGF-b in murine myeloid cell line. This is the ®rst report which reveals that Smad4 plays a critical role in TGF-b-mediated signaling in hematopoietic cells and indicates that genetic and functional mutations of the Smad4 gene should contribute to the development of human myelogeneous leukemia.
Materials and methods
Patients and cell preparation
Screening was performed for cases with AML and cell lines (THP1, P39TSU, HEL, U937, KG1, HL-60, MOLM13, GDM1, ML1, SKH1, JOSK-1, and CTV-1) derived from human myelogeneous leukemia. Diagnosis was made by the morphological analyses according to French-American-British (FAB) criteria (Bennett et al., 1991) . After obtaining informed consent, mononuclear cells were isolated from peripheral blood or bone marrow samples of patients by Ficoll ± Conray density gradient centrifugation. Total RNA of cells from the patients and the cell lines was extracted as described previously .
Reverse transcriptase-polymerase chain reaction-single-strand conformation polymorphism (RT ± PCR ± SSCP)
We analysed the status of the eight exons (exons 1 ± 3 and 7 ± 11) of the Smad4 gene. Point mutations, small nucleotide deletions, and insertions in these exons were examined by the RT ± PCR ± SSCP and sequencing analyses according to the previously described methodology (Hangaishi et al., 1996) . cDNAs were synthesized using total RNA and random hexamer primers with M-MLV reverse transcriptase (Life Technologies, Inc., Gaithersburg, MD, USA). The primary cDNA products were ampli®ed by PCR with the following primers: 5'-GGAAAAACTTGAACAAATGGACA-3' and 5'-AGCCTCCCATCCAATGTTCT-3' for exon 1; 5'-CATA-CAGAGAACATTGGATGGG-3' and 5'-TCATACTTGAT-GGAGCATTACTCT-3' for exons 2 and 3; 5'-GGCCTGTT-CACAATGAGCTT-3' and 5'-ACCTTTGCCTATGTGCA-ACC-3' for exons 7 and 8; 5'-GGTTGCACATAGGCAAA-GGT-3' and 5'-CAGGGATGTTTCCTGCCAC-3' for exons 9 and 10; 5'-CTGGCCCAGGATCAGTAGGT-3' and 5'-CC-CAACGGTAAAAGACCTCA-3' for exon 11. PCR products that showed polymorphic bands were subcloned into pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA), and two independent clones were sequenced in both directions to con®rm mutations.
Plasmid constructions
For construction of expression vectors for Smad3-Flag and Smad4-Flag, the BamHI ± HindIII fragment of Smad3-Flag and the EcoRI ± HindIII fragment of Smad4-Flag were excised from those placed in pRK5 (Zhang et al., 1996) (kind gifts from Dr R Derynck, UCSF). The resultant HindIII end of each fragment was changed into the XhoI end, and subcloned into pCMV5 (a kind gift from Dr JL Wrana, Hospital for Sick Children, Toronto, Ontario, Canada). For Smad4-HA, the corresponding fragments were subcloned into pCMV5. To generate the Flag-tagged constructs of Smad4 mutants, we replaced the EcoRI ± NspI or BglII ± XhoI fragment of pCMV5-Smad4-Flag with the corresponding fragment derived from cDNAs of the patients. p3TP-Lux was kindly provided by Dr K Miyazono (Department of Biochemistry, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan) (Nakao et al., 1997). To make the in-frame glutathione S-transferase (GST)-Smad3 fusion construct, the BamHI ± HindIII fragment of Smad3 was inserted into pEBG, the mammalian GST fusion protein expression vector (Imai et al., 1998) . To generate pMEneoSmad4P102L-Flag and pMEneo-Smad4D(483 ± 552)-Flag, the EcoRI ± XhoI fragments of the Flag-tagged Smad4 mutants were inserted into pME18Sneo (Liu et al., 1993) .
Cell culture and DNA transfection
HepG2, COS-7, and 293 cells were cultured in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS). CTV-1, KG-1, and Jurkat cells were maintained in RPMI 1640 with 10% FCS. 32Dcl3 cells were maintained in RPMI 1640 with 10% FCS and 0.25 ng of murine interleukine-3 (IL-3) per ml. HepG2 cells were transiently transfected with expression and reporter plasmids using a LipofectAMINE protocol (Life Technologies, Inc., Gaithersburg, MD, USA). COS-7 cells were transfected with expression plasmids by the DEAE-dextran method as described previously (Tanaka et al,. 1995a ). The 293 cells were transfected with expression plasmids by using SuperFect Transfection Reagents (Qiagen Inc, Hilden, Germany). 32Dcl3 cells were transfected with pMEneo-Smad4P102L-Flag or pMEneo-Smad4D(483 ± 552)-Flag, and stable transfectants were isolated as described previously (Tanaka et al., 1995b) .
Transcriptional response assays
Luciferase assays were performed as described previously (Tanaka et al., 1995b) . Brie¯y, reporter and expression plasmids were transfected into HepG2 cells by a LipofectA-MINE protocol. For analysis of luciferase activities observed in cotransfection with several expression plasmids, the equivalent-molar plasmid DNAs were transfected and the total amount of DNA in terms of weight was adjusted to be equal by adding the plasmid pUC13. HepG2 cells were cultured in DMEM containing 10% FCS for 30 to 36 h, and then harvested and subjected to the luciferase assay. The data were normalized by using the internal control of transfection eciency, as described previously .
In vivo binding assays
We coexpressed GST or the GST fusion protein of Smad3 with Smad4-Flag or its derivatives in COS-7 cells. Cells indicated were lysed in the TNE buer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 1 mM ethylenediamidetetraacetic acid) containing phosphatase inhibitors (12.5 mM b-glycerophosphate, 1 mM sodium orthovanadate) and a cocktail of proteinase inhibitors (10 U/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 5 mg/ml leupeptin, 1 mg/ml pepstatin A, 2 mM benzamidine, 1 mg/ml antipain, 1 mg/ml chymostatin and 2 mg/ml soybean trypsin inhibitor), and followed by recovery of GST or the fusion protein on glutathione-Sepharose (Amersham Pharmacia Biotech, Arlington Heights, IL, USA) beads and extensive washing with the TNE buer. Washed beads were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS ± PAGE) and Western blotting with the anti-Flag M2 monoclonal antibody (Sigma Bio Sciences, St. Louis, MO, USA). In COS-7 cells, Smad4-HA was coexpressed with Smad4-Flag or its derivatives, and the cells were lysed in the TNE buer. The cell lysates were precleared by protein GSepharose, mixed with the anti-Flag M2 monoclonal antibody (Sigma Bio Sciences), rotated for 3 h at 48C, and followed by recovery of the Flag-tagged protein on protein G-Sepharose beads. The beads were washed and subjected to SDS ± PAGE and Western blotting with the anti-HA antibody (12CA5, Boehringer Mannheim, Mannheim, Germany). The anti-GST antibody was prepared as described elsewhere (Imai et al., 1998) .
Immunofluorescence COS-7 cells were transfected with expression vectors, treated with the anti-HA and the anti-Flag antibodies in the absence or the presence of 5 ng/ml TGF-b (Boehringer Mannheim) and then incubated with¯uorescein isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG and Texas-red-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA), respectively as secondary antibodies. Images were obtained and analysed as described previously (Kurokawa et al., 1998b) .
Electrophoretic mobility shift assay (EMSA)
Smad4-Flag and its derivative were transfected into 293 cells. Forty-eight hours after transfection, the cells were lysed in the TNE buer described above, and the Flag-tagged proteins were isolated by immunoprecipitation with the anti-Flag M2 anity gel (Sigma Bio Sciences). Proteins were eluted from the antibody column with the elution solution containing 1 mg of the Flag peptide (Sigma Bio Sciences) per ml, incubated with the radioisotope-labeled probe, and EMSA was performed as described previously (Stroschein et al., 1999) . The probe, which includes the Smad-binding element, was produced by annealing oligonucleotides: 5'-GATCGAGAGTCTGGACACGTGGGGAGTCAGCCG-3' and 5'-GATCCGGCTGACTCCCCACGTGTCCAGACTCTC-3'. For radioisotope labeling, [a-32 P]dCTP was incorporated into the probe by incubation with the Klenow fragment.
Proliferation assays of the cell lines with TGF-b
Proliferation assays of CTV-1, KG-1, and Jurkat cell lines with TGF-b were performed as described previously (Piacibello et al., 1991) . Brie¯y, 5610 4 cells per ml were cultured in 2 ml of RPMI 1640 with or without various concentrations of TGF-b and 10% FCS. Viable cells were counted by the trypan blue exclusion method at each time point.
